Beximco Pharmaceuticals (DHA:BXPHARMA) Total Liabilities : BDT19,813 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals Total Liabilities?

Beximco Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was BDT19,813 Mil.

Beximco Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2023 (BDT21,537.12 Mil) to Dec. 2023 (BDT21,582.94 Mil) but then declined from Dec. 2023 (BDT21,582.94 Mil) to Mar. 2024 (BDT19,812.72 Mil).

Beximco Pharmaceuticals's annual Total Liabilities increased from Jun. 2021 (BDT14,881.22 Mil) to Jun. 2022 (BDT21,512.03 Mil) and increased from Jun. 2022 (BDT21,512.03 Mil) to Jun. 2023 (BDT21,537.12 Mil).

Beximco Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Beximco Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Total Liabilities Chart

Beximco Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

19,349.77

17,321.29

14,881.22

21,512.03

21,537.12

Beximco Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															23,590.48	22,215.43	21,537.12	21,582.94	19,812.72

Beximco Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Beximco Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	13265.024	+	(2550.833	+	2550.496
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	3170.764)
	=	21,537

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	69156.783	-	47619.666
	=	21,537

Beximco Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12142.091	+	(1603.815	+	2503.474
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	3563.337)
	=	19,813

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	70223.294	-	50410.577
	=	19,813

Beximco Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » Total Liabilities

Traded in Other Exchanges

BXP:UK R2WA:Germany

Address

19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205

Website

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines